RV-1770 is under clinical development by RNAimmune Inc and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase I drugs for Respiratory Syncytial Virus (RSV) Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the RV-1770 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RV-1770 overview
RV-1770 is under development for the prevention of respiratory syncytial virus infection. It is an mRNA vaccine delivered through polypeptide lipid nanoparticle (PLNP) based carrier. It is being developed based on mRNA Design Platform. It is administered through intramuscular route.
RNAimmune Inc overview
RNAimmune is a leading biopharmaceutical company in the field of messenger RNA (mRNA) therapeutics and vaccines. RNAimmune leverages mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. RNAimmune is a spin-off venture from Sirnaomics, receiving a global exclusive right of the proprietary PLNP technology for mRNA delivery, and proprietary know-how for large scale cGMP production of its mRNA products, possesses an in-house developed proprietary AI algorithm (ALEPVA) for antigen prediction and vaccine design.
For a complete picture of RV-1770’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
